Fresenius SE & Co. KGaA (BIT:1FRE)

Italy flag Italy · Delayed Price · Currency is EUR
44.09
-0.45 (-1.01%)
At close: Mar 27, 2026
Market Cap24.82B +11.1%
Revenue (ttm)22.87B +4.5%
Net Income1.26B
EPS2.24
Shares Outn/a
PE Ratio19.63
Forward PE12.13
Dividend1.00 (2.25%)
Ex-Dividend DateMay 26, 2025
Volumen/a
Average Volume92
Open44.09
Previous Close44.54
Day's Range44.09 - 44.09
52-Week Range34.50 - 52.36
Betan/a
RSI32.84
Earnings DateMay 6, 2026

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod... [Read more]

Industry Miscellaneous Health And Allied Services, Not Elsewhere Classified
Founded 1912
Employees 155,186
Stock Exchange Borsa Italiana
Ticker Symbol 1FRE

Financial Performance

Financial Statements

News

EQS-DD: Fresenius SE & Co. KGaA: Sara Hennicken, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 16.03.2026 / 17:10 CET/CEST The issuer is solely responsi...

11 days ago - Wallstreet:Online

Glenmark Pharmaceuticals to launch Potassium Phosphates Injection in March 2026

Glenmark Pharmaceuticals Inc., USA, is set to launch its Potassium Phosphates Injection USP in March 2026, offering single-dose vials and pharmacy bulk package vials. The product is bioequivalent to F...

11 days ago - Business Upturn

EQS-DD: Fresenius SE & Co. KGaA: Michael Sen, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 06.03.2026 / 10:45 CET/CEST The issuer is solely responsi...

21 days ago - Wallstreet:Online

EQS-PVR: Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe...

24 days ago - Wallstreet:Online

Fresenius SE & Co. KGaA (FSNUY) Q4 2025 Earnings Call Transcript

Fresenius SE & Co. KGaA (FSNUY) Q4 2025 Earnings Call Transcript

4 weeks ago - Seeking Alpha

Fresenius SE & Co KGaA (FSNUY) Full Year 2025 Earnings Call Highlights: Strong Organic ...

Fresenius SE & Co KGaA (FSNUY) Full Year 2025 Earnings Call Highlights: Strong Organic Growth and Strategic Flexibility

4 weeks ago - GuruFocus

Full Year 2025 Fresenius SE & Co KGaA Earnings Call Transcript

Full Year 2025 Fresenius SE & Co KGaA Earnings Call Transcript

4 weeks ago - GuruFocus

Fresenius SE & Co. (FSNUF) Reports Strong FY Core EPS Growth

Fresenius SE & Co. (FSNUF) Reports Strong FY Core EPS Growth

4 weeks ago - GuruFocus

Fresenius SE & Co. KGaA (FSNUY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Fresenius SE & Co. KGaA (FSNUY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2 months ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript

Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript

3 months ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUY) Q3 2025 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUY) Q3 2025 Earnings Call November 5, 2025 7:30 AM EST Company Participants Nick Stone - Senior VP of Investor Relations & Head of Investor Relations - Fresenius Mana...

5 months ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q2 2025 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2025 Earnings Conference Call August 6, 2025 7:30 AM ET Company Participants Michael Sen - CEO, President & Chairman of Management Board of Fresenius Managemen...

8 months ago - Seeking Alpha

Fresenius: Healthy Portfolio Add

International stocks are essential for portfolio diversification and can provide access to more attractive valuations. Fresenius is a leading global healthcare company with a strong presence and €21.5...

10 months ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q1 2025 Earnings Conference Call May 7, 2025 7:30 AM ET Company Participants Nick Stone - Head of Investor Relations Michael Sen - Chairman of the Management Boar...

11 months ago - Seeking Alpha

Fresenius posts profit beat in first quarter, confirms outlook

German healthcare group Fresenius beat analysts' adjusted operating profit expectations for the first quarter on Wednesday, citing a strong performance at its drug making division Kabi.

11 months ago - Reuters

Fresenius: Turnaround For Company, Stock Price

Fresenius SE has shown significant improvement, with a 50% stock price increase and strong financial results, including a 50.6% rise in operating income. The company's restructuring into two segments,...

1 year ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Full Year and Q4 2024 Earnings Call Transcript

Call Start: 7:30 January 1, 0000 8:50 AM ET Fresenius SE & Co. KGaA (OTCPK:FSNUF) Full Year and Q4 2024 Earnings Conference Call February 26, 2025 7:30 AM ET Company Participants Nick Stone – Head of ...

1 year ago - Seeking Alpha

Fresenius: The Signs Of A Significant Turnaround Are Getting Clearer And Clearer

Fresenius is showing significant upside, with a 25% RoR since early 2024, driven by strong earnings growth and strategic execution. The company's turnaround is evident with improved EPS, reduced lever...

1 year ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q3 2024 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2024 Results Conference Call November 6, 2024 7:30 AM ET Company Participants Nick Stone - Vice President of Investor Relations Michael Sen - Chief Executive O...

1 year ago - Seeking Alpha

Fresenius SE Raises Guidance After Strong Kabi, Helios Performances

The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.

1 year ago - WSJ

Fresenius: Showing Signs Of Recovery, We Have Dawn

Fresenius is showing early signs of recovery, with improved profitability and a simplified structure, making it a promising investment despite past delays. The company's divestments and deleveraging e...

1 year ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q2 2024 Earnings Call Transcript

Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2024 Earnings Conference Call July 31, 2024 7:30 AM ET Company Participants Markus Georgi - Head of Investor Relations. Michael Sen - Chief Executive Officer S...

1 year ago - Seeking Alpha

Fresenius: It's Darkest Before The Dawn

Fresenius, a German healthcare company, has the potential for significant growth and a near-term turnaround. The company is in the midst of a restructuring and has met its revenue and earnings targets...

2 years ago - Seeking Alpha

Fresenius SE: Hoping For The Turnaround In 2024

Fresenius reported mediocre results and suspended the dividend this year, but management is optimistic for fiscal 2024. The company will focus on reducing debt levels in 2024 and the deconsolidation o...

2 years ago - Seeking Alpha

Fresenius SE & Co. KGaA (FSNUF) Q4 2023 Earnings Call Transcript

Fresenius SE & Co. KGaA (FSNUF) Q4 2023 Earnings Call Transcript

2 years ago - Seeking Alpha